M

Merge Labs

Develops high-bandwidth brain–computer interfaces

Scientist – Synthetic Biology

Full-Time
$120k - $165k/yr
Expert
PhD
San Francisco, CA, USA
In Person
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • A PhD in Synthetic Biology, Bioengineering, Molecular Biology, or a related field, or equivalent experience leading research projects end-to-end.
  • A strong record of designing and experimentally validating mammalian gene circuits or tunable expression systems.
  • Proficiency in molecular cloning, library construction, mammalian cell expression, and quantitative characterization using methods such as flow cytometry, quantitative polymerase chain reaction (qPCR), sequencing, imaging, or functional assays.
  • Experience establishing systematic or high-throughput construct-testing workflows.
  • The ability to define a research strategy, troubleshoot at the bench, and drive ambiguous programs from concept through interpretable data.
Responsibilities
  • Design and implement mammalian genetic-circuit strategies to control component stoichiometry, expression level, timing, cell-type specificity, and cellular burden in multicomponent payloads.
  • Build and characterize synthetic constructs at high throughput using modular libraries of promoters, untranslated regions (UTRs), introns, polyadenylation signals, codon usage, gene order, polycistronic elements, and other regulatory sequences.
  • Develop compact expression-control systems such as inducible switches, dual-vector logic, feedback circuits, and microRNA-based regulation to safeguard against overexpression and off-target expression.
  • Engineer host-cell compatibility by addressing protein trafficking and turnover, proteostasis, metabolic burden, cellular stress, intracellular immune sensing, and transgene silencing; evaluate chaperone co-expression or degradation-control strategies where appropriate.
  • Translate expression requirements into payload architectures compatible with viral and non-viral delivery technologies.
  • Characterize expression and function in mammalian cells and neurons using quantitative readouts for dynamic range, leakiness, kinetics, stoichiometry, protein stability, cellular burden, stress responses, transgene silencing, and potential toxicity.
  • Evaluate lead payloads in animal models in collaboration with the in vivo operations team.
Desired Qualifications
  • Experience with neuronal, induced pluripotent stem cell-derived (iPSC-derived), or primary-cell models and in vivo translation.
  • Experience with payload design for viral or non-viral delivery technologies.
  • Expertise in RNA regulation, aptazymes, microRNA-based control, UTR and mRNA-stability engineering, intracellular immune sensing or transgene silencing, or cell-type-specific expression.
  • Experience engineering multicomponent protein systems or modeling circuit behavior and expression dynamics.

About the company

Merge Labs develops brain–computer interfaces to connect human brains with computers. Its product focus is high-bandwidth neural implants that read neural signals and transmit data to AI systems and software, enabling bidirectional communication between brain and machine. The implants are designed to work with advances in AI and neural sensing hardware, using a system of implants, interfaces, and software to interpret brain activity and control devices or software. Compared with competitors, Merge Labs aligns with Sam Altman’s vision of human–machine convergence, leveraging OpenAI ventures connections and positioning itself as a Neuralink rival with an emphasis on higher data throughput and scalable AI-assisted interpretation. The company’s goal is to create seamless, high-bandwidth brain–computer communication that enhances human capabilities and enables new ways of interacting with technology.

Company Size

51-200

Company Stage

Seed

Total Funding

$252M

Headquarters

San Francisco, California

Founded

2025

Get referred to Merge Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Butterfly's September 1, 2026 deal creates a commercial supply chain immediately.
  • OpenAI pledged scientific foundation models and frontier tools to accelerate Merge's R&D.
  • Ultrasound BCI leverages Butterfly's 71.4% gross margin platform and semiconductor manufacturing.

What critics are saying

  • A $252 million seed round funds research, not FDA-approved products or revenue.
  • Neuralink's implant-first progress and clinical visibility threaten Merge's noninvasive positioning.
  • OpenAI's insider support invites governance scrutiny if Merge misses milestones before 2027.

What makes Merge Labs unique

  • OpenAI invested in Merge Labs' $252 million seed round at an $850 million valuation.
  • Merge Labs uses ultrasound-on-chip from Butterfly Network, unlike Neuralink's invasive electrodes.
  • Sam Altman, OpenAI, and Forest Neurotech give Merge exceptional AI and neuroscience access.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-8%

2 year growth

-8%
Yahoo Finance
Sep 3rd, 2026
Sam Altman-backed Merge Labs selects Butterfly Network as exclusive ultrasound chip supplier for brain interfaces

Merge Labs, a brain-interface startup backed by OpenAI and Sam Altman, has selected Butterfly Network as its exclusive ultrasound-on-chip supplier under a multiyear agreement. The deal includes upfront payments, development milestones, purchase commitments, access fees, and potential royalties, though specific amounts were not disclosed. Butterfly's semiconductor-based ultrasound architecture makes the system programmable and easier to embed in new devices. The company retained rights to license its technology to other partners. Butterfly's second-quarter revenue increased 39% to $32.6 million, with gross margin expanding to 71.4%. Adjusted EBITDA loss narrowed 78% to $1.4 million. Management raised full-year revenue guidance to $119 million to $123 million. Thirty-three hedge funds held Butterfly Network in the second quarter, up from 26 in the first quarter.

Florida Today
Feb 14th, 2026
OpenAI invests in Merge Labs at $850M valuation

OpenAI has invested in Merge Labs at an $850 million valuation, according to reports. The investment focuses on scalable AI backends, including AICC technology. Details about the funding round, including the investment amount and other participants, were not disclosed. The partnership appears aimed at advancing AI infrastructure and backend capabilities. Merge Labs is working on developing scalable systems to support AI applications. The company's technology is designed to handle the computational demands of modern AI models. The investment represents OpenAI's continued expansion beyond its core business into supporting technologies and infrastructure for artificial intelligence development.

TechCrunch
Jan 16th, 2026
OpenAI invests in Sam Altman’s brain computer interface startup Merge Labs | TechCrunch

Merge Labs is a “research lab” dedicated to “bridging biological and artificial intelligence to maximize human ability.” OpenAI wrote the largest check in Merge Labs' $250 million seed round at an $850 million valuation.

Bloomberg Law
Jan 15th, 2026
Sam Altman's Merge raises $252M to connect human brains to computers

Merge Labs, co-founded by AI billionaire Sam Altman, has raised $252 million to develop devices connecting human brains to computers. The company aims to seamlessly link people and artificial intelligence to "maximise human ability, agency, and experience". The funding reflects growing Silicon Valley interest in brain-computer interfaces as entrepreneurs anticipate a future where AI becomes so advanced that humans may need to augment their brains to keep pace. Similar to how smartphones provide digital access, experimental brain technology is being designed to streamline human interaction with AI systems. The investment underscores the increasing focus on neurotechnology as a key frontier in the race to integrate artificial intelligence into human capabilities.

Wired
Dec 19th, 2025
Sam Altman’s New Brain Venture, Merge Labs, Will Spin Out of a Nonprofit

Merge Labs, a brain-computer interface startup that seeks to read brain activity using ultrasound, is being spun out of Forest Neurotech, a Los Angeles nonprofit.